Added to YB: 2024-04-16
Pitch date: 2024-04-07
HROW [bullish]
Harrow, Inc.
+158.5%
current return
Author Info
No bio for this author
Company Info
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States.
Market Cap
$1.3B
Pitch Price
$13.59
Price Target
N/A
Dividend
N/A
EV/EBITDA
29.74
P/E
-253.44
EV/Sales
5.49
Sector
Pharmaceuticals
Category
growth
Harrow, Inc.: Cleared vision?
HROW: Bullish 2024 case sees $205M rev (57% YoY) from $50M Iheezo (CMS approval key), $140M compounding/Fab4/Santen (10% growth), $15M Vevye (DED drug w/ $1.5B+ potential). Flat $162M costs + $21M debt = $22M pre-tax profit ($0.63/sh, 21x). Risks: AR balloon, Iheezo demand drop post-Dec, new accounting confusion.
Read full article (14 min)